NPPA allows increase in price of Ringer Lactate -RL Injection With Special Packaging
New Delhi: The National Pharmaceutical Pricing Authority has approved a marginal increase in the ceiling price of 4 pack sizes of Ringer lactate injection possessing special features by 0.53638 per cent, in line with the wholesale price index for the year 2020 over 2019.
With this, the cost of Ringer Lactate (RL) 100 ml injection has been revised to Rs 24.08 which was earlier priced at Rs 23.51. Similarly, now the price of the RL injection in the strength 250ml is Rs 41.60, 500 ml is Rs 52.31 and 1000 ml is Rs 91.95.
The special features possessed by the 4 pack sizes of Ringer lactate injection include self collapsibility and self-sealability, not having air-vent and no chance of contamination during manufacture/ infusion/ admixing levels.
Lactated Ringer's solution, or LR, is one of the two most common intravenous (IV) fluids used in patient care at hospitals.
Medical dialogues team had earlier reported that NPPA had decided to give a 15 per cent increment to the pricing of Ringer lactate injection (RL) with special packaging that had reduced chances of contamination of the product.
Now in line with the wholesale price index, exercising powers conferred by sub paragraph (3) and (4) of paragraph 11 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30th May, 2013, S.O. 1192(E) dated 22nd March, 2016 issued by the Government of India in the Ministry of Chemicals and Fertilizers and in supersession of the order of the Government of India in the Ministry of Chemicals and Fertilizers (National Pharmaceutical Pricing Authority) No. S.O 1216(E) dated 25.03.2020, SO. 2824(E) dated 20.08.2020, SO. 3321(E) dated 25.09.2020, SO. 3975(E) dated 03.11.2020 and SO. 521(E) dated 04.02.2021, in so far as it relates to ringer lactate injection in pack having special features like (i) self collapsibility and self-sealability (ii) not having air-vent and (iii) there is no chance of contamination during manufacture/ infusion/ admixing levels, manufactured by the manufacturers specified in Table B for specified products and pack-sizes, except in respect of things done or omitted to be done before such supersession, the National Pharmaceutical Pricing Authority, hereby revises the price based on Wholesale price index (WPI) of 2020 as specified in column (5) of the Table A herein below as separate ceiling price exclusive of goods and services tax applicable, if any in respect of the scheduled formulations specified in the corresponding entry in column (2) of the said Table with the dosage form and strength and unit/packaging specified respectively in the corresponding entries in columns (3) and (4) thereof:
Dosage form and Strength
Ceiling price (w.e.f. 01.04.2021 with WPI @
Each 100 ml pack having special features
Injection 250 ml
Each 250 ml pack having special features
Injection 500 ml
Each 500 ml pack having special features
Injection 1000 ml
Each 1000 ml pack having special features
Name of Manufacturer
M/s Albert David Ltd.
M/s Aculife Healthcare Pvt. Ltd.
M/s B. Braun Medical (India) Pvt. Ltd.
M/s Fresenius Kabi India Pvt. Ltd.
M/s Ostuka Pharmaceuticals India Pvt. Ltd.
M/s Denis Chem lab Ltd.
M/s Amanta Healthcare Ltd.
M/s Shree Krishna Keshav Laboratories Ltd.
M/s Axa Parenterals Ltd.
M/s Rusoma Laboratories Pvt. Ltd.
M/s R. K. Laboratories Pvt. Ltd.
M/s Realcade Lifescience Pvt. Ltd.
The notification further added;
(a) The ceiling prices are applicable with effect from 01.04.2021 (ceiling prices are inclusive of Wholesale Price Index (WPI) @0.53638% for the year 2020 over 2019).
(b) The manufacturers of scheduled formulations, selling abovesaid products/brand name of scheduled formulations at price higher than the ceiling price (plus goods and services tax as applicable) so fixed and notified by the Government, shall revise the prices of all such formulations downward not exceeding the ceiling price specified in column (5) in the above table plus goods and services tax as applicable if any.
(c) The manufacturers of above mentioned scheduled formulations having MRP lower than the ceiling price specified in column (5) in the above table (plus goods and services tax as applicable, if any), may revise the existing M.R.P. of their formulations, on the basis of WPI @ 0.53638% for the year 2020 in accordance with paragraph 16(2) of DPCO, 2013, read with para 13(2) of DPCO, 2013.
(d) The manufacturers may add goods and services tax only if they have paid actually or if it is payable to the Government on the ceiling price mentioned in column (5) of the above-said table.
(e) Any other manufacturer claiming separate ceiling price for ringer lactate injection in the pack having special features like (i) self collapsibility and self-sealability (ii) not having air-vent and (iii) there is no chance of contamination during manufacture/ infusion/ admixing levels shall apply to NPPA for separate ceiling price approval.
(f) For other special features claimed or any other pack size manufactured, the manufacturer shall approach the NPPA for specific price approval for its formulation
(g) The ceiling price for a pack of the scheduled formulation shall be arrived at by the concerned manufacturer in accordance with the ceiling price specified in column (5) of the above table as per provisions contained in paragraph 11 of the Drugs (Prices Control) Order, 2013. The manufacturer shall issue a price list in Form–V from the date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller and dealers.
(h) As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same.
(i) Where an existing manufacturer of scheduled formulation with dosage or strength or both as specified in the above table launches a new drug as per paragraph 2 (u) of the DPCO, 2013 such existing manufacturer shall apply for prior price approval of such new drug to the NPPA in Form I as specified under Schedule-II of the DPCO, 2013.
(j) The manufacturers of above said scheduled formulations shall furnish a quarterly return to the NPPA, in respect of production/import and sale of scheduled formulations in Form-III of Schedule-II of the DPCO, 2013 through IPDMS. Any manufacturer intending to discontinue production of above said scheduled formulation shall furnish information to the NPPA, in respect of discontinuation of production and/or import of scheduled formulation in Form-IV of Schedule-II of the DPCO, 2013 at least six months prior to the intended date of discontinuation.
(k) The manufacturers not complying with the ceiling price and notes specified hereinabove shall be liable to deposit the overcharged amount along with interest thereon under the provisions of the Drugs (Prices Control) Order, 2013 read with Essential Commodities Act, 1955.
(l) Consequent to the issue of ceiling prices of such formulations as specified in column (2) of the above table in this notification, the price order(s) fixing ceiling or retail price, if any, issued prior to the above said date of notification, stand(s) superseded.